Skip to main content Accessibility help

Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia

  • T. Möllers (a1) (a2) (a3), L. Perna (a2) (a4), H. Stocker (a1) (a2) (a3), P. Ihle (a5), I. Schubert (a5), B. Schöttker (a1) (a2), L. Frölich (a6), J. Bauer (a1) (a7) and H. Brenner (a1) (a2)...



The use of Alzheimer disease medication for the treatment of dementia symptoms has shown significant benefits with regards to functional and cognitive outcomes as well as nursing home placement (NHP) and mortality. Hospitalisations in these patient groups are characterised by extended length of stays (LOS), frequent readmissions, frequent NHP and high-mortality rates. The impact of Alzheimer disease medication on the aforementioned outcomes remains still unknown. This study assessed the association of Alzheimer disease medication with outcomes of hospitalisation among patients with Alzheimer disease and other forms of dementia.


A dynamic retrospective cohort study from 2004 to 2015 was conducted which claims data from a German health insurance company. People with dementia (PWD) were identified using ICD-10 codes and diagnostic measures. The main predictor of interest was the use of Alzheimer disease medication. Hospitalisation outcomes included LOS, readmissions, NHP and mortality during and after hospitalisation across four hospitalisations. Confounding was addressed using a propensity score throughout all analyses.


A total of 1380 users of Alzheimer disease medication and 6730 non-users were identified. The use of Alzheimer disease medication was associated with significantly shorter LOS during the first hospitalisations with estimates for the second, third and fourth showed a tendency towards shorter hospital stays. In addition, current users of Alzheimer disease medication had a lower risk of hospital readmission after the first two hospitalisations. These associations were not significant for the third and fourth hospitalisations. Post-hospitalisation NHP and mortality rates also tended to be lower among current users than among non-users but differences did not reach statistical significance.


Our results indicate that Alzheimer disease medication might contribute to a reduction of the LOS and the number of readmissions in PWD.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia
      Available formats


This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (, which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author

Author for correspondence: Tobias Möllers, E-mail:


Hide All
Abe, Y, Shimokado, K and Fushimi, K (2018) Donepezil is associated with decreased in-hospital mortality as a result of pneumonia among older patients with dementia: a retrospective cohort study. Geriatrics & Gerontology International 18, 269275.
Anderson, K, Bird, M, Blair, A and MacPherson, S (2016) Development and effectiveness of an integrated inpatient and community service for challenging behaviour in late life: from confused and disturbed elderly to transitional behavioural assessment and intervention service. Dementia (London) 15, 13401357.
Attems, J and Jellinger, K (2014) The overlap between vascular disease and Alzheimer's disease – lessons from pathology. BMC Medicine 12, 206, Doi: 10.1186/s12916-014-0206-2.
Bail, K, Berry, H, Grealish, L, Draper, B, Karmel, R, Gibson, D and Peut, A (2013) Potentially preventable complications of urinary tract infections, pressure areas, pneumonia, and delirium in hospitalised dementia patients: retrospective cohort study. BMJ Open 3, e002770.
Black, CM, Fillit, H, Xie, L, Hu, X, Kariburyo, MF, Ambegaonkar, BM, Baser, O, Yuce, H and Khandker, RK (2018) Economic burden, mortality, and institutionalization in patients newly diagnosed with Alzheimer's disease. Journal of Alzheimer's Disease 61, 185193.
Bohlken, J, Schulz, M, Rapp, MA and Batzing-Feigenbaum, J (2015) Pharmacotherapy of dementia in Germany: results from a nationwide claims database. European Neuropsychopharmacology 25, 23332338.
Chiu, A, Nguyen, HV, Reutens, S, Grace, D, Schmidtman, R, Shen, Q, Chen, J and Chan, DK (2009) Clinical outcomes and length of stay of a co-located psychogeriatric and geriatric unit. Archives of Gerontology and Geriatrics 49, 233236.
Conde-Sala, JL, Turro-Garriga, O, Pinan-Hernandez, S, Portellano-Ortiz, C, Vinas-Diez, V, Gascon-Bayarri, J and Rene-Ramirez, R (2016) Effects of anosognosia and neuropsychiatric symptoms on the quality of life of patients with Alzheimer's disease: a 24-month follow-up study. International Journal of Geriatric Psychiatry 31, 109119.
Dautzenberg, PL, Mulder, LJ, Olde Rikkert, MG, Wouters, CJ and Loonen, AJ (2004) Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage. International Journal of Geriatric Psychiatry 19, 641644.
Dou, KX, Tan, MS, Tan, CC, Cao, XP, Hou, XH, Guo, QH, Tan, L, Mok, V and Yu, JT (2018) Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. Alzheimer's Research & Therapy 10, 126, Doi: 10.1186/s13195-018-0457-9.
Eloniemi-Sulkava, U, Saarenheimo, M, Laakkonen, ML, Pietila, M, Savikko, N, Kautiainen, H, Tilvis, RS and Pitkala, KH (2009) Family care as collaboration: effectiveness of a multicomponent support program for elderly couples with dementia. Randomized controlled intervention study. Journal of the American Geriatrics Society 57, 22002208.
Fox, M, Persaud, M, Maimets, I, Brooks, D, O' Brien, K and Tregunno, D (2013) Effectiveness of early discharge planning in acutely ill or injured hospitalized older adults: a systematic review and meta-analysis. BMC Geriatrics 13, 70, Doi: 10.1186/1471-2318-13-70.
Gauthier, S, Loft, H and Cummings, J (2008) Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. International Journal of Geriatric Psychiatry 23, 537545.
German Society for Psychiatry, Psychotherapy, Psychosomotics and Neurology, German Society for Neurology (2016) S3-Guidelines ‘Dementia’. Available at (Accessed 04 October 2019) (in German).
Gill, S, Anderson, G, Fischer, H, Bell, C, Li, P, Normand, SL and Rochon, P (2009) Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors. Archives of Internal Medicine 169, 867873.
Gnjidic, D, Agogo, GO, Ramsey, CM, Moga, DC and Allore, H (2018) The impact of dementia diagnosis on patterns of potentially inappropriate medication use among older adults. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 73, 14101417.
Haaksma, ML, Vilela, LR, Marengoni, A, Calderon-Larranaga, A, Leoutsakos, JS, Olde Rikkert, MGM and Melis, RJF (2017) Comorbidity and progression of late onset Alzheimer's disease: a systematic review. PLoS One 12, e0177044.
Howard, R, McShane, R, Lindesay, J, Ritchie, C, Baldwin, A, Barber, R, Burns, A, Deinig, T, Findlay, D, Holmes, C, Hughes, A, Jacoby, R, Jones, R, Jones, R, McKeith, I, Macharouthu, A, O' Brien, J, Passmore, P, Sheehan, B, Juszczak, E, Katona, C, Hills, R, Knapp, M, Ballard, C, Brown, R, Banerjee, S, Onions, C, Griffin, M, Adams, J, Gray, R, Johnson, T, Bentham, P and Phillips, P (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. The New England Journal of Medicine 366, 893903.
Hurt, C, Bhattacharyya, S, Burns, A, Camus, V, Liperoti, R, Marriott, A, Nobili, F, Robert, P, Tsolaki, M, Vellas, B, Verhey, F and Byrne, EJ (2008) Patient and caregiver perspectives of quality of life in dementia. An investigation of the relationship to behavioural and psychological symptoms in dementia. Dementia and Geriatric Cognitive Disorders 26, 138146.
Ihle, P, Koster, I, Herholz, H, Rambow-Bertram, P, Schardt, T and Schubert, I (2005) Sample survey of persons insured in statutory health insurance institutions in Hessen – concept and realisation of person-related data base. Gesundheitswesen 67, 638645.
Isik, AT, Soysal, P, Stubbs, B, Solmi, M, Basso, C, Maggi, S, Schofield, P, Veronese, N and Mueller, C (2018) Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia: a meta-analysis and systematic review. Journal of the American Geriatrics Society 66, 18051811.
Jellinger, KA and Attems, J (2015) Challenges of multimorbidity of the aging brain: a critical update. Journal of Neural Transmission (Vienna) 122, 505521.
Kavanagh, S, Gaudig, M, Van Baelen, B, Adami, M, Delgado, A, Guzman, C, Jedenius, E and Schauble, B (2011) Galantamine and behavior in Alzheimer disease: analysis of four trials. Acta Neurologica Scandinavica 124, 302308.
Kim, DH, Brown, RT, Ding, EL, Kiel, DP and Berry, SD (2011) Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. Journal of the American Geriatrics Society 59, 10191031.
Koehler, BE, Richter, KM, Youngblood, L, Cohen, BA, Prengler, ID, Cheng, D and Masica, AL (2009) Reduction of 30-day postdischarge hospital readmission or emergency department (ED) visit rates in high-risk elderly medical patients through delivery of a targeted care bundle. Journal of Hospital Medicine 4, 211218.
Ku, LE, Li, CY and Sun, Y (2018) Can persistence with cholinesterase inhibitor treatment lower mortality and health-care costs among patients with Alzheimer's disease? A population-based study in Taiwan. American Journal of Alzheimer's Disease & Other Dementias 33, 8692.
Lampela, P, Tolppanen, AM, Tanskanen, A, Tiihonen, J, Lavikainen, P, Hartikainen, S and Taipale, H (2017) Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease. Annals of Medicine 49, 230239.
Lehmann, J, Michalowsky, B, Kaczynski, A, Thyrian, JR, Schenk, NS, Esser, A, Zwingmann, I and Hoffmann, W (2018) The impact of hospitalization on readmission, institutionalization, and mortality of people with dementia: a systematic review and meta-analysis. Journal of Alzheimer's Disease 64, 735749.
Matsunaga, S, Kishi, T, Yasue, I and Iwata, N (2015) Cholinesterase inhibitors for Lewy body disorders: a meta-analysis. International Journal of Neuropsychopharmacology 19, 115.
McKeith, IG, Boeve, BF, Dickson, DW, Halliday, G, Taylor, J-P, Weinstraub, D, Aarsland, D, Galvin, J, Attems, J, Ballard, CG, Bayston, A, Beach, TG, Bohnen, N, Bonanni, L, Bras, J, Brundin, P, Burn, D, Chen-Plotkin, A, Duda, JE, El-Agnaf, O, Feldman, H, Ferman, TJ, Ffytche, D, Fujishiro, H, Galasko, D, Goldman, JG, Gomperts, SN, Graff-Radford, NR, Honig, LS, Iranzo, A, Kantarci, K, Kaufer, D, Kukull, W, Lee, VMY, Leverenz, JB, Lewis, S, Lippa, C, Lunde, A, Masellis, M, Masliah, E, McLean, P, Mollenhauer, B, Montine, TJ, Moreno, E, Mori, E, Murray, M, O' Brien, JT, Orimo, S, Postuma, RB, Ramaswamy, S, Ross, OA, Salmon, DP, Singleton, A, Taylor, A, Thomas, A, Tiraboschi, P, Toledo, JB, Trojanowski, JQ, Tsuang, D, Walker, Z, Yamada, M and Kosaka, K (2017) Diagnosis and management of dementia with Lewy bodies, Fourth consensus report of the DLB Consortium. Neurology 89, 88100.
Michalowsky, B, Thyrian, JR, Eichler, T, Hertel, J, Wucherer, D, Flessa, S and Hoffmann, W (2016) Economic analysis of formal care, informal care, and productivity losses in primary care patients who screened positive for dementia in Germany. Journal of Alzheimer's Disease 50, 4759.
Mittelman, MS, Haley, WE, Clay, OJ and Roth, D (2006) Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology 67, 15921599.
Möllers, T, Stocker, H, Wei, W, Perna, L and Brenner, H (2019a) Length of hospital stay and dementia: a systematic review of observational studies. International Journal of Geriatric Psychiatry 34, 821.
Möllers, T, Perna, L, Ihle, P, Schubert, I, Bauer, J and Brenner, H (2019b) Factors associated with length of stay in hospital patients with and without dementia. Journal of Alzheimer's Disease 67, 10551065.
Mueller, C, Perera, G, Hayes, RD, Shetty, H and Stewart, R (2018 a) Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis. Age and Ageing 47, 8894.
Mueller, C, Perera, G, Rajkumar, AP, Bhattarai, M, Price, A, O'Brien, JT, Ballard, C, Stewart, R and Aarsland, D (2018 b) Hospitalization in people with dementia with Lewy bodies: frequency, duration, and cost implications. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 10, 143152.
Naylor, MD, Hirschman, KB, Hanlon, AL, Bowles, KH, Bradway, C, McCauley, KM and Pauly, MV (2014) Comparison of evidence-based interventions on outcomes of hospitalized, cognitively impaired older adults. Journal of Comparative Effectiveness Research 3, 245257.
Park-Wyllie, LY, Mamdani, MM, Li, P, Gill, SS, Laupacis, A and Juurlink, DN (2009) Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Medicine 6, e1000157.
Pasina, L, Cortesi, L, Tiraboschi, M, Nobili, A, Lanzo, G, Tettamanti, M, Franchi, C, Mannucci, PM, Ghidoni, S, Assolari, A, Brucato, A and Investigators, R (2018) Risk factors for three-month mortality after discharge in a cohort of non-oncologic hospitalized elderly patients: Results from the REPOSI study. Archives of Gerontology and Geriatrics 74, 169173.
Pedone, C, Ercolani, S, Catani, M, Maggio, D, Ruggiero, C, Quartesan, R, Senin, U, Mecocci, P and Cherbuini, A (2005) Elderly patients with cognitive impairment have a high risk for functional decline during hospitalization: the GIFA Study. The Journals of Gerontology. Series A, Biological sciences and Medical Sciences 60, 15761580.
Pickens, S, Naik, AD, Catic, A and Kunik, ME (2017) Dementia and hospital readmission rates: a systematic review. Dementia and Geriatric Cognitive Disorders Extra 7, 346353.
Pilotto, A, Polidori, MC, Veronese, N, Panza, F, Arboretti Giancristofaro, R, Pilotto, A, Daragjati, J, Carrozzo, E, Prete, C, Gallina, P, Padovani, A, Maggi, S and Multidimensional Prognostic Index_Age Project, I. (2018) Association of antidementia drugs and mortality in community-dwelling frail older patients with dementia: the role of mortality risk assessment. Journal of the American Medical Directors Association 19, 162168.
Poulin, SP, Bergeron, D and Dickerson, BC (2017) Risk factors, neuroanatomical correlates, and outcome of neuropsychiatric symptoms in Alzheimer's disease. Journal of Alzheimer's Disease 60, 483493.
Ready, RE, Ott, BR and Grace, J (2004) Patient versus informant perspectives of quality of life in mild cognitive impairment and Alzheimer's disease. International Journal of Geriatric Psychiatry 19, 256265.
Reynish, EL, Hapca, SM, De Souza, N, Cvoro, V, Donnan, PT and Guthrie, B (2017) Epidemiology and outcomes of people with dementia, delirium, and unspecified cognitive impairment in the general hospital: prospective cohort study of 10,014 admissions. BMC Medicine 15, 140, Doi: 10.1186/s12916-017-0899-0.
Schneeweiss, S, Rassen, JA, Glynn, RJ, Avorn, J, Mogun, H and Brookhart, MA (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20, 512522.
Schüssler, S and Lohrmann, C (2015) Change in care dependency and nursing care problems in nursing home residents with and without dementia: a 2-year panel study. PLoS One 10, e0141653.
Solomon, A, Dobranici, L, Kareholt, I, Tudose, C and Lazarescu, M (2011) Comorbidity and the rate of cognitive decline in patients with Alzheimer dementia. International Journal of Geriatric Psychiatry 26, 12441251.
Spencer, K, Foster, P, Whittamore, KH, Goldberg, S and Harwood, R (2013) Delivering dementia care differently – evaluating the differences and similarities between a specialist medical and mental health unit and standard acute care wards: a qualitative study of family carers’ perceptions of quality of care. BMJ Open 3, e004198.
Tay, FHE, Thompson, CL, Nieh, CM, Nieh, CC, Koh, HM, Tan, JJC and Yap, PLK (2018) Person-centered care for older people with dementia in the acute hospital. Alzheimer's & Dementia: the Journal of the Alzheimer's Association 4, 1927.
Trinh, N, Hoblyn, J, Mohanty, S and Yaffe, K (2003) Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. The Journal of the American Medical Association 289, 210216.
Vann Jones, SA and O'Brien, JT (2014) The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychological Medicine 44, 673683.
Watkin, L, Blanchard, MR, Tookman, A and Sampson, EL (2012) Prospective cohort study of adverse events in older people admitted to the acute general hospital: risk factors and the impact of dementia. International Journal of Geriatric Psychiatry 27, 7682.
Wattmo, C, Londos, E and Minthon, L (2018) Short-term response to cholinesterase inhibitors in Alzheimer's disease delays time to nursing home placement. Current Alzheimer Research 15, 905916.
Wilcock, G, Ballard, C, Cooper, J and Loft, H (2008) Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Journal of Clinical Psychiatry 69, 341348.
Youn, YC, Shin, HW, Choi, BS, Kim, S, Lee, JY and Ha, YC (2017) Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment. International Journal of Geriatric Psychiatry 32, 10791084.
Zhu, CW, Livote, EE, Scarmeas, N, Albert, M, Brandt, J, Blacker, D, Sano, M and Stern, Y (2013) Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease. Alzheimer's & Dementia: the Journal of the Alzheimer's Association 9, 733740.
Zhu, CW, Cosentino, S, Ornstein, K, Gu, Y, Andrews, H and Stern, Y (2015) Use and cost of hospitalization in dementia: longitudinal results from a community-based study. International Journal of Geriatric Psychiatry 30, 833841.


Type Description Title
Supplementary materials

Möllers et al. supplementary material
Tables S1-S4

 Word (21 KB)
21 KB

Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia

  • T. Möllers (a1) (a2) (a3), L. Perna (a2) (a4), H. Stocker (a1) (a2) (a3), P. Ihle (a5), I. Schubert (a5), B. Schöttker (a1) (a2), L. Frölich (a6), J. Bauer (a1) (a7) and H. Brenner (a1) (a2)...


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed